In silico approach to screen compounds active against parasitic nematodes of major socio-economic importance

BMC Bioinformatics

Volumn 12, Issue SUPPL. 13, 2011, Pages

  Khanna, Varun ^a   Ranganathan, Shoba ^a,b  

^a MACQUARIE UNIVERSITY   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DEVELOPING COUNTRIES; DIAGNOSIS; LEARNING SYSTEMS; RADIAL BASIS FUNCTION NETWORKS; SUPPORT VECTOR MACHINES;

ANTIPARASITIC DRUGS; COMMERCIAL INCENTIVES; COMPUTATIONAL APPROACH; MACHINE LEARNING MODELS; MECHANISM OF ACTION; RADIAL BASIS FUNCTION KERNELS; SCIENTIFIC KNOWLEDGE; SUPPORT VECTOR MACHINE ALGORITHM;

CLASSIFICATION (OF INFORMATION);

NEMATODA;

ANTHELMINTIC AGENT;

ALGORITHM; ANIMAL; ARTICLE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; NEMATODE; NEMATODIASIS; PARASITOLOGY; SUPPORT VECTOR MACHINE;

ALGORITHMS; ANIMALS; ANTHELMINTICS; DRUG DISCOVERY; HUMANS; NEMATODA; NEMATODE INFECTIONS; SUPPORT VECTOR MACHINES;

MLCS; MLOWN;

EID: 84864045320     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-S13-S25     Document Type: Article

References (49)

1. Ranganathan S, Menon R, Gasser RB. Advanced in silico analysis of expressed sequence tag (EST) data for parasitic nematodes of major socio-economic importance-fundamental insights toward biotechnological outcomes. Biotechnol Adv 2009, 27(4):439-448. 10.1016/j.biotechadv.2009.03.005, 19345258.
2. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990, 6(4):112-115. 10.1016/0169-4758(90)90227-U, 15463312.
3. Friedman PA, Platzer EG. Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. Biochim Biophys Acta 1980, 630(2):271-278. 10.1016/0304-4165(80)90431-6, 7388055.
4. Kohler P, Bachmann R. Intestinal tubulin as possible target for the chemotherapeutic action of mebendazole in parasitic nematodes. Mol Biochem Parasitol 1981, 4(5-6):325-336. 10.1016/0166-6851(81)90064-5, 7335116.
5. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, Arena JP. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994, 371(6499):707-711. 10.1038/371707a0, 7935817.
6. Holden-Dye L, Walker RJ. Avermectin and avermectin derivatives are antagonists at the 4-aminobutyric acid (GABA) receptor on the somatic muscle cells of Ascaris; is this the site of anthelmintic action?. Parasitology 1990, 101(Pt 2):265-271.
7. Bokisch AJ, Walker RJ. The action of Avermectin (MK 936) on identified central neurones from Helix and its interaction with acetylcholine and gamma-aminobutyric acid (GABA) responses. Comp Biochem Physiol C 1986, 84(1):119-125. 10.1016/0742-8413(86)90176-3, 2873943.
8. Martin RJ, Verma S, Levandoski M, Clark CL, Qian H, Stewart M, Robertson AP. Drug resistance and neurotransmitter receptors of nematodes: recent studies on the mode of action of levamisole. Parasitology 2005, 131(Suppl):S71-84.
9. Sutherland IA, Leathwick DM. Anthelmintic resistance in nematode parasites of cattle: a global issue?. Trends Parasitol 2011, 27(4):176-181. 10.1016/j.pt.2010.11.008, 21168366.
10. James CE, Hudson AL, Davey MW. Drug resistance mechanisms in helminths: is it survival of the fittest?. Trends in Parasitology 2009, 25(7):328-335. 10.1016/j.pt.2009.04.004, 19541539.
11. Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 2000, 13(2):207-222. 10.1128/CMR.13.2.207-222.2000, 100151, 10755998.
12. Keiser J, Utzinger J, Xiao-Nong RBRO, Jürg U. The drugs we have and the drugs we need against major helminth infections. Advances in Parasitology 2010, 73:197-230. Academic Press.
13. Kaminsky R, Ducray P, Jung M, Clover R, Rufener L, Bouvier J, Weber SS, Wenger A, Wieland-Berghausen S, Goebel T, et al. A new class of anthelmintics effective against drug-resistant nematodes. Nature 2008, 452(7184):176-180. 10.1038/nature06722, 18337814.
14. Hu Y, Xiao SH, Aroian RV. The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist. PLoS Negl Trop Dis 2009, 3(8):e499. 10.1371/journal.pntd.0000499, 2715879, 19668355.
15. Harder A, von Samson-Himmelstjerna G. Cyclooctadepsipeptides--a new class of anthelmintically active compounds. Parasitol Res 2002, 88(6):481-488. 10.1007/s00436-002-0619-2, 12107468.
16. Harder A, Schmitt-Wrede HP, Krucken J, Marinovski P, Wunderlich F, Willson J, Amliwala K, Holden-Dye L, Walker R. Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents 2003, 22(3):318-331. 10.1016/S0924-8579(03)00219-X, 13678839.
17. Keiser J, Chollet J, Xiao S-H, Mei J-Y, Jiao P-Y, Utzinger J, Tanner M. Mefloquine-" an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009, 3(1):e350. 10.1371/journal.pntd.0000350, 2600813, 19125172.
18. Xiao S-H, Keiser J, Chen M-G, Tanner M, Utzinger J, Xiao-Nong RBRO, Jürg U. Research and development of antischistosomal drugs in the people's republic of China: a 60-year review. Advances in Parasitology 2010, 73:231-295. Academic Press.
19. Marrero-Ponce Y, Castillo-Garit JA, Olazabal E, Serrano HS, Morales A, Castanedo N, Ibarra-Velarde F, Huesca-Guillen A, Jorge E, del Valle A, et al. TOMOCOMD-CARDD, a novel approach for computer-aided 'rational' drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J Comput Aided Mol Des 2004, 18(10):615-634. 10.1007/s10822-004-5171-y, 15849993.
20. Reddy S, Pati P, Kumar P, Pradeep HN, Sastry N. Virtual screening in drug discovery -- a computational perspective. Current protein & peptide science 2007, 8(4):329-351.
21. Freitas RF, Oprea TI, Montanari CA. 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L. Bioorganic & Medicinal Chemistry 2008, 16(2):838-853. 10.1016/j.bmc.2007.10.048, 3191738, 22007153.
22. Sousa S, Fernandes P, Ramos M. Protein-ligand docking: Current status and future challenges. Proteins 2006, 65(1):15-26. 10.1002/prot.21082, 16862531.
23. Geppert H, Vogt M, Bajorath J. Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation. Journal of Chemical Information and Modeling 2010, 50(2):205-216. 10.1021/ci900419k, 20088575.
24. Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. Journal of Chemical Information and Computer Sciences 2003, 43(6):2048-2056. 10.1021/ci0340916, 14632457.
25. Warmuth MK, Liao J, Ratsch G, Mathieson M, Putta S, Lemmen C. Active learning with support vector machines in the drug discovery process. Journal of Chemical Information and Computer Sciences 2003, 43(2):667-673. 10.1021/ci025620t, 12653536.
26. Burbidge R, Trotter M, Buxton B, Holden S. Drug design by machine learning: support vector machines for pharmaceutical data analysis. Computers & Chemistry 2001, 26(1):5-14.
27. Woods D, Williams T. The challenges of developing novel antiparasitic drugs. Invertebrate Neuroscience 2007, 7(4):245-250. 10.1007/s10158-007-0055-1, 18004600.
28. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Molecular Informatics 2010, 29(6-7):476-488.
29. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Research 2009, 37(suppl 2):W623-W633. 2703903, 19498078.
30. Holden-Dye L, Walker RJ. Anthelmintic drugs. WormBook 2007, 1-13.
31. Mayer AM, Hamann MT. Marine pharmacology in 2001--2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2005, 140(3-4):265-286. 10.1016/j.cca.2005.04.004, 15919242.
32. Mayer AM, Rodriguez AD, Berlinck RG, Hamann MT. Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2007, 145(4):553-581. 10.1016/j.cbpc.2007.01.015, 2151674, 17392033.
33. Mayer AM, Rodriguez AD, Berlinck RG, Hamann MT. Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim Biophys Acta 2009, 1790(5):283-308. 10.1016/j.bbagen.2009.03.011, 2735450, 19303911.
34. Wishart D, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research 2008, 36(Database issue):D901-906. 2238889, 18048412.
35. Trotter MWB, Holden SB. Support vector machines for ADME property classification. Qsar & Combinatorial Science 2003, 22(5):533-548. 10.1002/qsar.200310006, 22006830.
36. Overington J. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. J Comput Aided Mol Des 2009, 23(4):195-198. 10.1007/s10822-009-9260-9, 19194660.
37. Pipeline Pilot. , http://accelrys.com/
38. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. Journal of Medicinal Chemistry 1996, 39(15):2887-2893. 10.1021/jm9602928, 8709122.
39. Dutta D, Guha R, Wild D, Chen T. Ensemble feature selection: consistent descriptor subsets for multiple QSAR models. Journal of Chemical Information and Modeling 2007, 47(3):989-997. 10.1021/ci600563w, 17407280.
40. Duch W. Filter Methods. Feature Extraction: Foundations and Applications 2006, 207. Berlin, Germany: Springer, Guyon I, Gunn S, Nikravesh M, Zadeh L.
41. Marchiori E, Moore J, Soto A, Cecchini R, Vazquez G, Ponzoni I. A wrapper-based feature selection method for ADMET prediction using evolutionary computing. Evolutionary Computation, Machine Learning and Data Mining in Bioinformatics 2008, 4973:188-199. Springer Berlin / Heidelberg.
42. MOE(2009.10). , http://www.chemcomp.com/
43. Jennrich RI. Stepwise discriminant analysis. Statistical methods for digital computers 1977, 3:76-96. New York: Wiley, Enslein K, Ralston A, Wilf HS.
44. Tanagra: free data mining software. , http://eric.univ-lyon2.fr/~ricco/tanagra/en/tanagra.html
45. Cortes C, Vapnik V. Support-vector networks. Machine Learning 1995, 20(3):273-297.
46. Jorissen RN, Gilson MK. Virtual screening of molecular databases using a support vector machine. Journal of Chemical Information and Modeling 2005, 45(3):549-561. 10.1021/ci049641u, 15921445.
47. Liew CY, Ma XH, Liu X, Yap CW. SVM model for virtual screening of Lck inhibitors. Journal of Chemical Information and Modeling 2009, 49(4):877-885. 10.1021/ci800387z, 19267483.
48. Byvatov E, Fechner U, Sadowski J, Schneider G. Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J Chem Inf Comput Sci 2003, 43(6):1882-1889. 10.1021/ci0341161, 14632437.
49. Ivanciuc O. Applications of support vector machines in chemistry. Reviews in Computational Chemistry 2007, 23:291-400.